New HIV-vaccine tested on peopleFebruary 14, 2012
Actually, medical science can control an HIV-infection quite well, with a medicine cocktail. 'Seropositive' people (people who are infected with the HIV virus) now can lead a reasonably normal life, but their virus is not exterminated. When they stop the treatment it immediately rebounds.
Science knows what the problem is: the 'special forces' in our blood (the CD8 cells, in medical lingo) get not enough support from the general staff (the dendritic cells, that show the combat units what to attack). Dendritic cells exhibit on their exterior typical parts of the virus to be attacked. But human dendritic cells are not that good in getting the right information on the HIV virus and to transform it into good examples for the CD8 battle cells.
The virologists and HIV-physicians of the Institute of Tropical Medicine and the haematologists of Antwerp University Hospital have cooperated for years on that problem. Together they succeeded to 'load' dendritic cells of seropositive volunteers in the lab with the building instructions (genetic information in the form of so-called messenger RNA) for HIV proteins. They could make the dendritic cells to execute the instructions and to exhibit the resulting typical part of the HIV virus on their surface. Subsequent research in test tubes demonstrated that the 'loaded' dendritic cells were able to activate battle cells.
Time had come to proceed to humans. Flemish, Belgian and French research foundations provided grants. Six seropositive persons who for a long time already used the drug cocktails, were prepared to volunteer. The scientists filtered the dendritic cells from a large volume of their blood, cultivated them in test tubes in the cell-therapy unit of the Antwerp University Hospital and provided them with the genetic instructions of an HIV virus. They then froze the loaded cells.
The volunteers received four times, with four-week intervals, a small quantity of their own reworked dendritic cells. And indeed, after each vaccination the CD8 battle cells in their bodies recognised the virus better and better, while the vaccination had virtually no side effects. The most important result was that the vaccine-activated battle cells became better and better in suppressing the virus, in test tubes for the moment. But HIV remains a disguise artist; it still succeeds in changing its proteins sufficiently fast and often to let at least a few viruses escape the attack.
So it remains impossible to cure AIDS, but the results are encouraging: the vaccine, made of the participant's own dendritic cells, is safe and has some therapeutic effect, be it a limited one. But sufficiently strong for a publication in the most renowned journal for HIV researchers, AIDS. And more than sufficient to enthuse and motivate the Antwerp scientists.
Institute of Tropical Medicine Antwerp
Related HIV Vaccine Current Events and HIV Vaccine News Articles
HIV-1 movement across genital tract cells surprisingly enhanced by usurping antibody response
Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself.
HIV vaccines elicit immune response in infants
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers, researchers at Duke Medicine report.
Scripps Research Institute Study Explores Barriers to HIV Vaccine Response
Researchers at The Scripps Research Institute (TSRI) discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins.
Mutations in a gene that impacts immune function increase susceptibility to prostate cancer
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.
OHSU research highlights promising strategy to help vaccines outsmart HIV
A new discovery at Oregon Health & Science University highlights an ingenious method to ensure the body effectively reacts when infected with the highly evasive HIV virus that causes AIDS.
Competing antibodies may have limited the protection achieved in HIV vaccine trial in Thailand
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
New vaccine-design approach targets HIV and other fast-mutating viruses
A team led by scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) has unveiled a new technique for vaccine design that could be particularly useful against HIV and other fast-changing viruses.
Study offers new way to discover HIV vaccine targets
Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.
Injection-free vaccination technique could address global vaccine challenge for HIV, malaria
Scientists at King's College London have demonstrated the ability to deliver a dried live vaccine to the skin without a traditional needle, and shown for the first time that this technique is powerful enough to enable specialised immune cells in the skin to kick-start the immunising properties of the vaccine.
Designer bacteria may lead to better vaccines
Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.
More HIV Vaccine Current Events and HIV Vaccine News Articles